BioCryst Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on BioCryst Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date BioCryst Pharmaceuticals Inc Strategy Report
- Understand BioCryst Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on BioCryst Pharmaceuticals Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| AU2018283053B2 | Grant | Imidazole-containing inhibitors of ALK2 kinase | A61K31/517; A61K31/519; A61K31/53; A61K31/5377; A61P19/00; A61P35/00; C07D233/64; C07D401/12; C07D401/14; C07D403/12; C07D403/14; C07D471/04; C07D487/04; C07D491/048; C07D495/04; C07D513/04 | September 08, 2022 |
| CA2941380C | Grant | HUMAN PLASMA KALLIKREIN INHIBITORS | A61K31/415; A61K31/4155; A61P1/02; A61P1/04; A61P11/04; A61P13/02; A61P13/12; A61P19/02; A61P25/00; A61P27/02; A61P29/00; A61P3/10; A61P31/04; A61P43/00; A61P7/00; A61P7/02; A61P7/04; A61P7/10; A61P9/00; A61P9/10; A61P9/12; C07D231/14; C07D401/04; C07D401/12; C07D401/14; C07D403/04; C07D403/12; C07D405/12; C07D413/04; C07D413/12; C07D417/12 | September 06, 2022 |
| ECSP22036455A | Application | INHIBIDORES DEL FACTOR D DEL COMPLEMENTO PARA ADMINISTRACI?N ORAL | A61K31/343; A61K31/443; A61K31/53; A61P25/00; A61P25/28; A61P9/00; C07D209/08; C07D307/79; C07D307/80; C07D307/81; C07D307/82; C07D401/04; C07D405/04; C07D405/12; C07D407/04; C07D409/04; C07D413/04; C07D417/04; C07D487/04; C07F9/2475 | August 31, 2022 |
| EP3828173B1 | Grant | SUBSTITUIERTE PYRAZOLE ALS MENSCHLICHE PLASMAKALLIKREINHEMMER | A61K31/415; A61K31/4155; A61P1/02; A61P1/04; A61P11/04; A61P13/02; A61P13/12; A61P19/02; A61P25/00; A61P27/02; A61P29/00; A61P3/10; A61P31/04; A61P43/00; A61P7/00; A61P7/02; A61P7/04; A61P7/10; A61P9/00; A61P9/10; A61P9/12; C07D231/14; C07D401/04; C07D401/12; C07D401/14; C07D403/04; C07D403/12; C07D405/12; C07D413/04; C07D413/12; C07D417/12 | August 31, 2022 |
| ECSP22036502A | Application | INHIBIDORES DEL FACTOR D DEL COMPLEMENTO PARA ADMINISTRACI?N ORAL | A61K31/343; A61K31/381; A61K31/404; A61K31/416; A61K31/437; A61K31/506; A61K31/5377; A61P13/12; A61P25/00; A61P25/28; A61P27/02; A61P7/00; A61P9/00; C07C217/48; C07D209/12; C07D231/56; C07D273/04; C07D275/04; C07D307/80; C07D333/56; C07D401/04; C07D405/04; C07D405/06; C07D405/10; C07D405/12; C07D407/12; C07D407/14; C07D417/12; C07D471/04; C07D491/048; C07D493/04; C07D495/04 | August 31, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer